
Next-gen TearScience
Johnson & Johnson Vision has unveiled its next-generation TearScience Activator Clear for more precise and fully automated treatment of meibomian gland dysfunction (MGD). The new system features a

Johnson & Johnson Vision has unveiled its next-generation TearScience Activator Clear for more precise and fully automated treatment of meibomian gland dysfunction (MGD). The new system features a

American actress and singer-songwriter Mandy Moore, the voice of Disney’s Princess Rapunzel, is a dry-eye sufferer and the new brand ambassador for Lumenis’ OptiLight.

Seattle start-up Olympic Ophthalmics has received US Food and Drug Administration (FDA) approval for its iTEAR100 device, a prescription neurostimulation therapy to increase tear production in adult

Launched during RANZCO’s virtual congress, Quantel Medical’s C.Stim offers new intense pulsed light (IPL) technology for the treatment of the root causes of dry eye: meibomian gland dysfunction, inflammation and Demodex.

The US Food and Drug Administration (FDA) has approved the first generic of Allergan’s Restasis (cyclosporine ophthalmic emulsion) 0.05% single-use eye drops to increase tear production in dry eye patients.

Focusing on dry eye disease (DED), the third Ocular Therapeutics Evening (OTE) finally went ahead after a five-month wait. It’s been a while since we had an in-person meeting, so it was great to see at least the top halves of some familiar faces again! It was also entertaining to see the Covid trace

Alcon has expanded its range of preservative-free eye drops for dry eye disease with the addition of Systane Complete Preservative-Free. Using Systane’s delivery system of hydroxypropyl-guar

Alcon has expanded its range of preservative-free eye drops for dry eye disease with the addition of Systane Complete Preservative-Free. Using Systane’s delivery system of hydroxypropyl-guar (HP-Guar)

A 52-year-old South-East Asian female presented to clinic for a routine eye exam. She had been experiencing some near blur and a constant gritty sensation in both eyes; otherwise, she had no notable symptoms. Her last medical exam was six months prior and she had hypercholesterolaemia that was under

Glaukos has enrolled its first patient for its phase 2 trials of GLK-301, a pilocarpine-based cream applied to the outer eyelid to treat dry eye disease (DED). The California-based ophthalmic

Lumenis is hosting a Dry Eye Summit live at the Sydney Hilton Hotel, providing an opportunity for educational discussion, collaboration and networking. The event will feature presentations from three

Of all the things we’ve had enough of lately, screen time is surely one. We might be navigating endless spreadsheets, overlapping Zoom meetings, frustrating home schooling, or helplessly doom-scrolling at midnight, but we’re also extremely fortunate to be able to learn and connect online.